|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
First published online September 16, 2009
doi: 10.1242/10.1242/jcs.050260
Opinion |
1 University of Oslo, Institute of Pathology, Rikshospitalet, N-0027 Oslo, Norway
2 Division of Pathology, Oslo University Hospital Rikshospitalet, Oslo, Norway
* Author for correspondence (i.h.madshus{at}medisin.uio.no)
Summary
The epidermal growth factor receptor (EGFR; also known as ErbB1) is one of four related receptor tyrosine kinases. These receptors (EGFR, ErbB2, ErbB3 and ErbB4) are frequently overexpressed in cancer and such overexpression is associated with poor clinical outcome. Understanding the mechanisms involved in growth-factor-receptor downregulation is medically important, as several drugs that interfere with the function and trafficking of ErbB proteins are currently being developed or are already in clinical trials. EGFR has become a model protein for understanding the biology and endocytosis of related growth-factor receptors, and the mechanisms involved in its endocytosis and degradation have been scrutinized for several decades. Nevertheless, the details and principles of these processes are still poorly understood and often controversial. In particular, the literature describing how the ubiquitylation and recruitment of EGFR to clathrin-coated pits are connected is inconsistent and confusing. In this Opinion article, we discuss the impact of signaling motifs, kinase activity and ubiquitylation on clathrin-dependent endocytosis and lysosomal sorting of EGFR. In addition, we discuss potential explanations for contradicting reports, and propose models for the recruitment of ligand-activated EGFR to clathrin-coated pits as well as for lysosomal sorting of ligand-activated EGFR.
Key words: EGF receptor, Clathrin, Endocytosis, Ubiquitin
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati
Twitter What's this?